492 related articles for article (PubMed ID: 18508981)
1. Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms.
He YX; Guo QY
Postgrad Med J; 2008 May; 84(991):246-51. PubMed ID: 18508981
[TBL] [Abstract][Full Text] [Related]
2. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
[TBL] [Abstract][Full Text] [Related]
3. [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
Buchmann I; Ganten TM; Haberkorn U
Z Gastroenterol; 2008 Apr; 46(4):367-75. PubMed ID: 18393156
[TBL] [Abstract][Full Text] [Related]
4. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
[TBL] [Abstract][Full Text] [Related]
5. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor.
Tsurusaki M; Okada M; Kuroda H; Matsuki M; Ishii K; Murakami T
J Gastroenterol; 2014 Jan; 49(1):46-56. PubMed ID: 23525980
[TBL] [Abstract][Full Text] [Related]
7. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors.
Song JY; Lee YN; Kim YS; Kim SG; Jin SJ; Park JM; Choi GS; Chung JC; Lee MH; Cho YH; Choi MH; Kim DC; Choi HJ; Moon JH; Lee SH; Jeong SW; Jang JY; Kim HS; Kim BS
Nucl Med Commun; 2015 Apr; 36(4):319-27. PubMed ID: 25564069
[TBL] [Abstract][Full Text] [Related]
8. Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma.
Kawamura E; Shiomi S; Kotani K; Kawabe J; Hagihara A; Fujii H; Uchida-Kobayashi S; Iwai S; Morikawa H; Enomoto M; Murakami Y; Tamori A; Kawada N
J Gastroenterol Hepatol; 2014 Sep; 29(9):1722-7. PubMed ID: 24730671
[TBL] [Abstract][Full Text] [Related]
9. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
Ho CL; Yu SC; Yeung DW
J Nucl Med; 2003 Feb; 44(2):213-21. PubMed ID: 12571212
[TBL] [Abstract][Full Text] [Related]
10. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
[TBL] [Abstract][Full Text] [Related]
11. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.
Yamamoto Y; Nishiyama Y; Kameyama R; Okano K; Kashiwagi H; Deguchi A; Kaji M; Ohkawa M
J Nucl Med; 2008 Aug; 49(8):1245-8. PubMed ID: 18632827
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of
Lee SM; Kim HS; Lee S; Lee JW
World J Gastroenterol; 2019 Mar; 25(11):1289-1306. PubMed ID: 30918424
[TBL] [Abstract][Full Text] [Related]
13. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy.
Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K
Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632
[TBL] [Abstract][Full Text] [Related]
14. [Malignant tumor with false negative 18F-FDG PET image].
Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
[TBL] [Abstract][Full Text] [Related]
15. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.
Lee M; Ko H; Yun M
Yonsei Med J; 2018 Dec; 59(10):1143-1149. PubMed ID: 30450847
[TBL] [Abstract][Full Text] [Related]
16. 18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.
Kirchner J; Sawicki LM; Deuschl C; Grüneisen J; Beiderwellen K; Lauenstein TC; Herrmann K; Forsting M; Heusch P; Umutlu L
PLoS One; 2017; 12(7):e0180349. PubMed ID: 28683109
[TBL] [Abstract][Full Text] [Related]
17. The role of (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis, staging, and follow-up of cholangiocarcinoma.
Moon CM; Bang S; Chung JB
Surg Oncol; 2011 Mar; 20(1):e10-7. PubMed ID: 19804967
[TBL] [Abstract][Full Text] [Related]
18. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma.
Lin WY; Tsai SC; Hung GU
Nucl Med Commun; 2005 Apr; 26(4):315-21. PubMed ID: 15753790
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic accuracy of 18F-FDG positron emission tomography for evaluation of hepatocellular carcinoma].
Shin JA; Park JW; An M; Choi JI; Kim SH; Kim SK; Lee WJ; Park SJ; Hong EK; Kim CM
Korean J Hepatol; 2006 Dec; 12(4):546-52. PubMed ID: 17237633
[TBL] [Abstract][Full Text] [Related]
20. Clinical Value of 18F-FDG PET/CT in Detecting Adrenal Metastasis in Patients with Hepatocellular Carcinoma.
Lin Y; Jeng LB; Wang HY; Tsai SC; Lin WY; Kao CH
Technol Cancer Res Treat; 2015 Oct; 14(5):593-9. PubMed ID: 24945368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]